Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12895244 | 0.94 | MAP2K1 (0.41) | MAP2K1ABCB11NQO2MAP2K2KCNH2 | |
| SCHEMBL12894927 | 0.91 | MAP2K1 (0.50) | MAP2K1MAP2K2KCNH2 | |
| SCHEMBL12895182 | 0.85 | MAP2K1 (0.48) | MAP2K1MAP2K2KCNH2 | |
| SCHEMBL1217020 | 0.84 | MAP2K1 (0.56) | MAP2K1MAP2K2 | |
| SCHEMBL14227911 | 0.83 | MAP2K1 (0.60) | MAP2K1ABCB11NQO2MAP2K2KCNH2 | |
| SCHEMBL1219314 | 0.78 | MAP2K1 (0.54) | MAP2K1MAP2K2 | |
| SCHEMBL1219042 | 0.78 | MAP2K1 (0.41) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL4000893 | 0.77 | GAA (0.44) | MAP2K1GAA | |
| SCHEMBL1216151 | 0.76 | MAP2K1 (0.44) | MAP2K1GAA | |
| SCHEMBL13062702 | 0.75 | MAP2K1 (0.51) | MAP2K1MAP2K2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893085-B2 | 3-(4-Bromo-2-fluoro-phenylamino)-thieno[3,2-c]pyridine-2-carboxylic acid (2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide; mitogen activated protein extracellular kinase kinase (MEK) inhibitor; antiproliferative, antiinflammatory agent | GENENTECH, INC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | MKI67, CDKN1A, MAP3K1 | MAP2K1 38/4885ABCB11 2030/4885NQO2 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.